Malaysia Ramps Up HPV Awareness To Combat Cervical Cancer

In a significant move to combat the prevalence of cervical cancer in Malaysia, GSK has aligned with the International Papillomavirus Society (IPVS) to mark the International HPV Awareness Day 2024. This initiative underscores the critical importance of public education on Human Papillomavirus (HPV) and its link to cervical cancer, which remains the fourth most common cancer among Malaysian women and the second most prevalent among those aged 15 to 44. The campaign, themed 'One Less Worry', emphasizes the preventability of this disease through effective screening and vaccination strategies.

Dr. Alap Gandhi, Country Medical Director of GSK Malaysia, lauded Malaysia's proactive measures towards eradicating cervical cancer, highlighting the nation's pioneering efforts since 2010. Professor Dr. Jamiyah Hassan, a Senior Consultant in O&G and Feto-Maternal Medicine at Hospital Al-Sultan Abdullah, echoed this sentiment. She pointed out the World Health Organization's (WHO) goal to reduce global cervical cancer rates by 2030 to below 4 per 100,000 women, emphasizing the disease's preventability through HPV prevention methods and sensitive screening tests.

HPV, a common sexually transmitted infection (STI), encompasses over 150 strains, making it almost inevitable for individuals to contract it at some point in their lives. While most HPV infections are harmless and self-resolving, certain high-risk strains can lead to severe health conditions, including various cancers. Women who engage in sexual activity at a young age or have multiple sexual partners face a higher risk of contracting these dangerous HPV strains.

The progression from HPV infection to cervical cancer typically spans 10 to 15 years, highlighting the importance of regular screenings and early detection in preventing cell mutation. Pap smears are recommended for women aged 21 to 29 every year for two years, followed by screenings every three years. Those up to age 65 should undergo screening once every five years. If HPV is detected, further tests assess the presence of abnormal cells to ensure early intervention.

GSK's commitment extends beyond awareness campaigns; by offering vaccines and specialized medicines, the company aims to bolster public health in Malaysia significantly. Achieving WHO's ambitious 90-70-90 targets by 2030—wherein 90% of girls are vaccinated against HPV by age 15, 70% of women are screened by ages 35 and again by 45, and 90% of those with cervical disease receive treatment—remains a pivotal goal in this ongoing battle against cervical cancer.

The concerted efforts by GSK and various stakeholders underscore a unified commitment to making HPV-related diseases #OneLessWorry for individuals worldwide, bringing us closer to eliminating cervical cancer as a public health issue.